行情

OMER

OMER

奥麦罗制药
NASDAQ

实时行情|Nasdaq Last Sale

15.84
+0.02
+0.13%
已收盘, 16:42 09/22 EDT
开盘
15.61
昨收
15.82
最高
16.07
最低
15.61
成交量
25.14万
成交额
--
52周最高
23.85
52周最低
9.25
市值
9.90亿
市盈率(TTM)
-6.9170
分时
5日
1月
3月
1年
5年
调查 Omeros 的资本使用回报率
According to data from Benzinga Pro, during Q2, Omeros's (NASDAQ:OMER) reported sales totaled $28.82 million. Despite a 21.55% increase in earnings, the company posted a loss of $24.02 million.
Benzinga · 2天前
Omeros (OMER) 报告第二季度亏损,高于收入预期
Zacks.com · 08/09 21:35
Omeros:第二季度收益洞察
Shares of Omeros (NASDAQ:OMER) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 24.59% year over year to ($0.46), which beat the estimate of ($0.57).
Benzinga · 08/09 20:58
Omeros Q2 每股收益 $(0.46) 超过 $(0.57) 预估,销售额为 2882 万美元,超过预估 2427 万美元
Omeros (NASDAQ:OMER) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.57) by 19.3 percent. This is a 24.59 percent increase over losses of $(0.61) per share from the same
Benzinga · 08/09 20:37
Omeros每股收益超过0.09美元,收入超过
Omeros (NASDAQ:OMER): Q2 GAAP EPS of -$0.46 beats by $0.09. Revenue of $28.8M (+112.9% Y/Y) beats by $4.53M. At June 30, 2021, Omeros had cash, cash equivalents and short-term investments
Seekingalpha · 08/09 20:08
Omeros Q2 亏损因收入增加而收窄——盘后股价上涨 3%
MT Newswires · 08/09 17:46
Omeros Corporation 将于 2021 年 8 月 9 日公布第二季度财务业绩
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 2021, after the market closes. Omeros management will host a conference call and we...
Business Wire · 08/03 12:30
收益预览:Omeros (OMER) Q2 收益预计下降
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/02 19:01
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解OMER最新的财务预测,通过OMER每股收益,每股净资产,每股现金流等数据分析奥麦罗制药近期的经营情况,然后做出明智的投资选择。
分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测OMER价格均价为37.43,最高价位100.00,最低价为18.00。
EPS
机构持股
总机构数: 192
机构持股: 3,376.77万
持股比例: 54.03%
总股本: 6,249.56万
类型机构数股数
增持
55
187.05万
建仓
18
64.16万
减持
39
429.01万
平仓
19
90.46万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.30%
制药与医学研究
-0.11%
高管信息
Chairman/President/Chief Executive Officer/Director
Gregory Demopulos
Chief Accounting Officer/Vice President - Finance/Treasurer
Michael Jacobsen
Chief Scientific Officer/Vice President
George Gaitanaris
Vice President/General Counsel/Secretary
Peter Cancelmo
Vice President/Director of Human Resources
Peter Williams
Vice President
Christopher Bral
Vice President
Nadia Dac
Vice President
Bruce Meiklejohn
Vice President
Catherine Melfi
Vice President
Tina Quinton
Vice President
J. Steven Whitaker
Vice President - Business Development
Timothy Duffy
Lead Director/Independent Director
Thomas Cable
Director
Peter Demopulos
Independent Director
Ray Aspiri
Independent Director
Thomas Bumol
Independent Director
Arnold Hanish
Independent Director
Leroy Hood
Independent Director
Rajiv Shah
Independent Director
Kurt Zumwalt
暂无数据
OMER 简况
Omeros Corporation是一家商业阶段的生物制药公司。该公司主要从事针对大型市场与孤儿适应症的小分子与蛋白质疗法的发现、开发和商业化业务,以治疗补体介导的中枢神经系统的炎症、疾病与紊乱。该公司的药品OMIDRIA(去氧肾上腺素和酮咯酸眼内溶液)用于白内障手术或人工晶状体(IOL)置换术中。该公司的临床阶段发展计划的重点是补体相关的血栓性微血管病变、补体介导的肾小球肾病、亨廷顿舞蹈病与认知障碍以及成瘾性与强迫性疾病。该公司还提供多种临床前程序和平台,用于解锁新的G蛋白偶联受体(GPCR)药物靶标和生成抗体。

微牛提供Omeros Corporation(NASDAQ-OMER)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的OMER股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易OMER股票基本功能。